Have you been diagnosed with a plasma cell disorder? You may be able to join a registry to help us learn more about the effects of plasma cell disorders on different aspects of life.
Have you been diagnosed with melanoma? If so, you may be eligible to take part in a research study looking at the safety of giving a combination of drugs called Ulixertinib and Palbociclib to patients with advanced melanoma.
The purpose of this study is to establish a safe dose of study cells to give to patients with relapsed/ refractory ALL expressing CD19.
Do you have lymphoma that has come back, or did not get better with the last treatment you were given? If so, you might able to participate in a study to see if the study team can make modified T cells that are able to fight and kill the lymphoma cells.
Do you have bladder, kidney, prostate, or another genitourinary cancer diagnosis? If so, you may be able to take part in a research study collecting specimens (e.g., blood, urine, saliva, tissue) during your already scheduled appointments. Collecting these specimens may help researchers develop new ways to detect cancer earlier or to more effectively treat cancer.
The primary objective of this repository is to make blood samples available for research studies related to histocompatibility and HC transplantation or other cellular therapy.
We will collect one more round of data from participants >= 45 years and analyze factors associated with aging and cognitive function.
This study seeks to better understand the unmet needs and care preferences of young adult cancer patients and their caregivers. Interviews to gather this information will be used to tailor an existing, evidence-based patient navigation program to these needs and preferences.
Pleuropulmonary Blastoma (PPB) is a rare lung tumor in young children that can grow in stages from less serious (Type I) to more dangerous (Type III). This study will test how well a drug combo: vincristine, topotecan, and cyclophosphamide (VTC) works for serious types (Type II and III) and help decide which patients with less serious tumors (Type I and Type Ir (regressed) PPB ) need chemotherapy after surgery. Researchers will also study the biology of the tumor to learn more about it.
The main goal of this project is to create an interactive online version of the Let's Talk program and test it with patients who have Lynch syndrome to see if it works well in a medical setting.